Trial Profile
An open-label, randomized, controlled trial to assess the efficacy and safety of teprenone in chronic hepatitis C patients concurrent with chronic gastritis treated with peginterferon alpha-2b plus ribavirin.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2021
Price :
$35
*
At a glance
- Drugs Teprenone (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Gastritis; Hepatitis C
- Focus Therapeutic Use
- 23 Apr 2021 Status changed from active, no longer recruiting to completed.
- 25 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan
- 26 Apr 2011 Planned end date changed from 1 Mar 2012 to 1 Dec 2013 as reported by University Hospital Medical Information Network - Japan